Anti-inflammatory agents other than corticosteroid in SARs-CoV-2 pneumonia | Zendy

Pongdhep Theerawit | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Anti-inflammatory agents other than corticosteroid in SARs-CoV-2 pneumonia

Author(s) -

Pongdhep Theerawit

Publication year - 2021

Publication title -

clinical critical care

Language(s) - English

Resource type - Journals

ISSN - 2774-0048

DOI - 10.54205/ccc.v29i.252686

Subject(s) - medicine , corticosteroid , pneumonia , complication , covid-19 , immunology , intensive care medicine , disease , infectious disease (medical specialty)

The SARs-CoV-2 results in hyperinflammation among infected patients. This condition leads to serious organ injury, especially in the lungs. Therefore, the main treatment option, in addition to anti-viral agents, is the administration of corticosteroids. However, in many cases, inadequate response to corticosteroids has been observed—other anti-inflammatory agents, such as interleukin-6 inhibitor, kinase inhibitor, etc., play an essential role in reducing this severe complication.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research